1. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors
- Author
-
Franck Mortreux, Philippe V. Afonso, Antoine Moriceau, Antoine Gessain, Frederic Toulza, Charles R. M. Bangham, Yves Plumelle, Eric Wattel, Mourad Mekaouche, Renaud Mahieux, Jérôme Estaquier, Olivier Hermine, Guy Dubreuil, Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Station de primatologie (SP), Centre National de la Recherche Scientifique (CNRS), Oncovirologie et Biothérapies, Department of Immunology, Imperial College London, Service de pharmacie, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie, Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique], Départment d'Hématologie, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-IFR10, Virologie humaine, École normale supérieure - Lyon (ENS Lyon)-IFR128-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), École normale supérieure de Lyon (ENS de Lyon)-IFR128-Institut National de la Santé et de la Recherche Médicale (INSERM), Virologie et pathogenèse virale (VPV), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Service d'Hematologie Biologique, CHU Fort de France, Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Virologie et pathogenèse virale ( VPV ), Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Cytokines, hématopoïèse et réponse immune ( CHRI ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut de biologie et chimie des protéines [Lyon] ( IBCP ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Slama, Catherine, and Gau, Mireille
- Subjects
Male ,MESH: Paraparesis, Tropical Spastic ,viruses ,MESH: T-Lymphocyte Subsets ,CD8-Positive T-Lymphocytes ,Biochemistry ,MESH: Antiretroviral Therapy, Highly Active ,0302 clinical medicine ,T-Lymphocyte Subsets ,Antiretroviral Therapy, Highly Active ,Tropical spastic paraparesis ,MESH: Animals ,MESH: Histone Deacetylase Inhibitors ,ComputingMilieux_MISCELLANEOUS ,MESH: Papio ,0303 health sciences ,education.field_of_study ,Deltaretrovirus Infections ,Hematology ,Reverse-transcriptase inhibitor ,Monkey Diseases ,MESH: Zidovudine ,Viral Load ,MESH: CD8-Positive T-Lymphocytes ,Paraparesis, Tropical Spastic ,3. Good health ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,MESH: Monkey Diseases ,Simian T-lymphotropic virus 1 ,MESH: Viral Load ,Zidovudine ,Viral load ,medicine.drug ,MESH: Antiviral Agents ,medicine.medical_specialty ,MESH: Simian T-lymphotropic virus 1 ,Immunology ,Population ,Biology ,Antiviral Agents ,03 medical and health sciences ,Internal medicine ,MESH: HTLV-I Infections ,medicine ,Animals ,Humans ,education ,[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology ,030304 developmental biology ,MESH: Humans ,Valproic Acid ,Cell Biology ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,bacterial infections and mycoses ,HTLV-I Infections ,Virology ,Reverse transcriptase ,MESH: Male ,Histone Deacetylase Inhibitors ,Disease Models, Animal ,MESH: Drug Therapy, Combination ,MESH: Reverse Transcriptase Inhibitors ,MESH: Disease Models, Animal ,Asymptomatic carrier ,MESH: Valproic Acid ,MESH: Female ,030217 neurology & neurosurgery ,MESH: Deltaretrovirus Infections ,Papio - Abstract
Approximately 3% of all human T-lymphotropic virus type 1 (HTLV-1)–infected persons will develop a disabling inflammatory disease of the central nervous system known as HTLV-1–associated myelopathy/tropical spastic paraparesis, against which there is currently no efficient treatment. As correlation exists between the proviral load (PVL) and the clinical status of the carrier, it is thought that diminishing the PVL could prevent later occurrence of the disease. We have conducted a study combining valproate, an inhibitor of histone deacetylases, and azidothymidine, an inhibitor of reverse transcriptase, in a series of baboons naturally infected with simian T-lymphotropic virus type 1 (STLV-1), whose PVL was equivalent to that of HTLV-1 asymptomatic carriers. We show that the combination of drugs caused a strong decrease in the PVL and prevented the transient rise in PVL that is seen after treatment with histone deacetylases alone. We then demonstrate that the PVL decline was associated with an increase in the STLV-1–specific cytotoxic T-cell population. We conclude that combined treatment with valproate to induce viral expression and azidothymidine to prevent viral propagation is a safe and effective means to decrease PVL in vivo. Such treatments may be useful to reduce the risk of HAM/TSP in asymptomatic carriers with a high PVL.
- Published
- 2010
- Full Text
- View/download PDF